IMNM Chief Medical Officer Robert Lechleider Buys $480K of Stock

Robert Lechleider, the Chief Medical Officer of Immunome, Inc. (NasdaqCM: IMNM), made a significant insider purchase on June 25, 2026. He bought 55,000 shares at an average price of $8.73 each, totaling approximately $480,150. This transaction was not part of a pre-planned trading program, indicating Lechleider's proactive decision to invest in the company.

Insider Buying and Selling at Immunome, Inc.

On June 25, 2026, Robert Lechleider, Immunome's Chief Medical Officer, purchased 55,000 shares at $8.73 each, totaling $480,150. This buy was not part of a Rule 10b5-1 trading plan. Additionally, on June 15, 2026, Max Rosett, Chief Financial Officer, bought 60,000 shares at $1.05 each, and later sold shares at higher prices as part of planned transactions.

Other Institutional Activity in Immunome

Several institutional investors have adjusted their positions in Immunome. FMR LLC increased its holdings by 420,238 shares, bringing its total to 16,969,954 shares valued at about $371.1 million, marking a 2.5% increase. T. Rowe Price Investment Management, Inc. added 2,942,024 shares, a 21.9% increase, resulting in a total of 16,364,011 shares worth approximately $357.9 million. BlackRock, Inc. grew its stake by 573,678 shares, a 7.6% rise, ending with 8,168,674 shares valued at $178.6 million. Conversely, Redmile Group, LLC trimmed its position by 159,500 shares, a 2.8% decrease, leaving it with 5,558,885 shares worth $121.6 million. State Street Corp increased its holdings significantly by 1,531,901 shares, a 39.6% rise, totaling 5,399,901 shares valued at $118.1 million.

Immunome, Inc. Stock Down 16.7%

Shares of Immunome, Inc. traded near $19.96 on Tuesday. The company, with a market capitalization of approximately $2.26 billion, is part of the biotechnology sector. It has a forward P/E ratio that isn't meaningful due to negative earnings. The stock's 52-week range spans from $7.96 to $27.65, and it has a beta of 2.07, indicating higher volatility compared to the market. Immunome's 50-day moving average is $21.25, and its 200-day moving average is $19.58. The company maintains a strong liquidity position, with a current ratio of 21.68 and a quick ratio of 21.26.

Analysts Set New Price Targets

Analysts remain bullish on Immunome, Inc. On June 12, 2026, Wedbush reiterated its 'buy' rating with a price target of $31. Truist Securities maintained a 'buy' rating on May 28, 2026, with a target of $37, while Barclays initiated coverage with a 'buy' and a $36 target on the same day. The consensus among 13 analysts is a 'buy' recommendation, with a target mean price of $35.77.

About Immunome, Inc.

Immunome, Inc. is a biotechnology company based in Bothell, Washington. It focuses on developing antibody-drug conjugates and other cancer treatments. The company is working on clinical assets like Varegacestat, which is in Phase 3 trials for desmoid tumors, and IM-1021, an ADC in Phase 1 trials. Immunome also has preclinical programs targeting solid tumors. Founded in 2006, the company is led by CEO Dr. Clay B. Siegall and employs around 206 people.

Bottom Line

Robert Lechleider's recent purchase of 55,000 shares underscores insider confidence in Immunome's prospects. Investors often watch such moves for insights into a company's potential trajectory. While the 13F filings and insider trades provide a historical snapshot, they offer valuable clues about management's outlook and institutional sentiment.